摘要
目的评价国产哌罗匹隆治疗精神分裂症的临床疗效和安全性。方法将47例符合中国精神障碍分类与诊断标准第3版(CCMD-3)精神分裂症诊断标准的患者随机分为哌罗匹隆组与氯氮平组,分别给予哌罗匹隆与氯氮平治疗,于治疗前和治疗后第2、4、6、8周末以阳性症状与阴性症状量表(PANSS)及不良反应量表(TESS)评定其疗效和不良反应。结果哌罗匹隆的有效率(81.8%)与氯氮平的有效率(80.0%)比较,差异无统计学意义(P>0.05),而哌罗匹隆组的不良反应少于氯氮平组(P<0.01)。结论国产哌罗匹隆治疗精神分裂症安全有效,患者的依从性较好。
Objective To evaluate the clinical efficacy and safety of domestic perospirone in the treatment of schizophrenia.Methods 47 patients who met diagnostic criteria for schizophrenia according to Chinese classification and diagnostic criteria of mental disorders 3rd edition（CCMD-3） were randomly divided into perospirone group and clozapine group,and perospirone or clozapine were administrated to the patients in the corresponding group.Positive and negative syndrome scale（PANSS） and treatment emergent symptom scale（TESS） were employed to assess their curative effect and side effects at the beginning of treatment and at the end of 2,4,6,8 weeks after treatment.Results Comparison with the effective rate of peospirone（81.8%） and that of clozpine（80.0%）,the difference showed no statistically significant（P0.05）,however,the side effects of patients in perospirone group were less than those in clozapine group（P0.01）.Conclusion Domestic perospirone is safe and effective in treatment of schizophrenia,with a better patient compliance.
出处
《重庆医学》
CAS
CSCD
北大核心
2011年第17期1680-1681,1684,共3页
Chongqing medicine
